KRAS and rectal cancer: (34) explored the changes in plasma ctDNA detectability in 33 patients before and one week after the initiation of Na-ChRT for rectal cancer using denaturing capillary electrophoresis as the first step and a high-resolution “BEAMING assay” directed at the detection of KRAS-specific ctDNA in a subgroup of patients.